Novigenix
Switzerland-based biotech company focused on Immuno-Transcriptomic oncology solutions
Lausanne, Switzerlandnovigenix.com ↗
Total raised
€22M
€21,800,000
Funding rounds
2
Investors
1
distinct backers
Active since
2022-12
latest 2025-04
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood43
base rate 45% for Grant
- ▲ In typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood12
base rate 12% (2+ rounds)
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-04-04 | Grant | €1.8M | European Union (EU) research initiative | View deal → |
| 2022-12-02 | Series B | €20M | — | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy